Ultragenyx Pharmaceutical (NASDAQ:RARE) Sets New 1-Year Low - Should You Sell?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) shares hit a new 52-week low on Friday . The company traded as low as $26.46 and last traded at $27.01, with a volume of 651521 shares changing hands. The stock had previously closed at $27.41.

Analyst Ratings Changes

Several research firms have commented on RARE. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price target on the stock. Morgan Stanley lowered their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday. Wells Fargo & Company lowered their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. Guggenheim reissued a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Finally, JPMorgan Chase & Co. increased their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $83.64.

Ultragenyx Pharmaceutical Trading Down 2.6%

The firm's 50-day moving average is $35.83 and its two-hundred day moving average is $38.36. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -4.55 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The firm's revenue was up 28.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.03) EPS. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 3,167 shares of company stock valued at $118,824. Corporate insiders own 5.50% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in RARE. California State Teachers Retirement System boosted its holdings in Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after buying an additional 268 shares in the last quarter. GAMMA Investing LLC raised its position in Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 323 shares during the last quarter. Xponance Inc. raised its position in Ultragenyx Pharmaceutical by 2.8% during the first quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after acquiring an additional 347 shares during the last quarter. BOKF NA raised its position in Ultragenyx Pharmaceutical by 5.0% during the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after acquiring an additional 382 shares during the last quarter. Finally, Oak Ridge Investments LLC raised its position in Ultragenyx Pharmaceutical by 2.3% during the first quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after acquiring an additional 395 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.